Results 21 to 30 of about 2,734,900 (203)

Eicosanoids in human heart failure: pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels

Archives of Medical Science, 2023
Introduction The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF). Material and methods We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET levels using ...
Petr Kala, Tomas Hnat, Karolina Padrova, Karel Kotaška, Josef Veselka   +4 more
doaj   +1 more source

Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and renin angiotensin system. [PDF]

PLoS ONE, 2015
Palmitoylethanolamide (PEA), a peroxisome proliferator-activated receptor-α agonist, has been demonstrated to reduce blood pressure and kidney damage secondary to hypertension in spontaneously hypertensive rat (SHR).
Giuseppina Mattace Raso, Claudio Pirozzi, Roberta d'Emmanuele di Villa Bianca, Raffaele Simeoli, Anna Santoro, Adriano Lama, Francesca Di Guida, Roberto Russo, Carmen De Caro, Raffaella Sorrentino, Antonio Calignano, Rosaria Meli   +11 more
doaj   +1 more source

Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome

Frontiers in Molecular Biosciences, 2021
Objectives: Cardiovascular diseases (CVD) remain the leading cause of morbimortality in patients with chronic kidney disease (CKD). The aim of this study was to assess the cardiovascular impact of the pharmacological inhibition of soluble epoxide ...
Mouad Hamzaoui, Mouad Hamzaoui, Clothilde Roche, David Coquerel, Thomas Duflot, Thomas Duflot, Valery Brunel, Paul Mulder, Vincent Richard, Jérémy Bellien, Jérémy Bellien, Dominique Guerrot, Dominique Guerrot   +12 more
doaj   +1 more source

Epoxyeicosatrienoic acids and cardioprotection: The road to translation [PDF]

Journal of Molecular and Cellular Cardiology, 2014
AbstractCardiovascular disease, including acute myocardial infarction (AMI), is the leading cause of morbidity and mortality globally, despite well-established treatments. The discovery and development of novel therapeutics that prevent the progression of devastating consequences following AMI are thus important in reducing the global burden of this ...
Oni-Orisan, Akinyemi, Alsaleh, Nasser, Lee, Craig R, Seubert, John M   +3 more
openaire   +4 more sources

Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer. [PDF]

Oncotarget, 2017
Epoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer. However, its role in the development of chemoresistant breast cancers has yet to be elucidated. Here, we found that
Thuy Phuong NT, Kim JW, Kim JA, Jeon JS, Lee JY, Xu WJ, Yang JW, Kim SK, Kang KW.   +8 more
europepmc   +2 more sources

Epoxyeicosatrienoic Acid Analogs and Vascular Function [PDF]

Current Medicinal Chemistry, 2010
Arachidonic acid metabolites, eicosanoids, are key contributors to vascular function and improper eicosanoid regulation contributes to the progression of cardiovascular diseases. Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid by epoxygenase enzymes to four regioisomers, 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. These EETs have
V, Sudhahar, S, Shaw, J D, Imig
openaire   +2 more sources

Vascular Pharmacology of Epoxyeicosatrienoic Acids [PDF]

, 2010
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid that are produced by the vascular endothelium in responses to various stimuli such as the agonists acetylcholine (ACH) or bradykinin or by shear stress which activates phospholipase A(2) to release arachidonic acid.
Sandra L, Pfister, Kathryn M, Gauthier, William B, Campbell   +2 more
openaire   +2 more sources

Epoxyeicosatrienoic acid metabolites inhibit Kir4.1/Kir5.1 in the distal convoluted tubule.

Am J Physiol Renal Physiol, 2020
Cytochrome P-450 (Cyp) epoxygenase-dependent metabolites of arachidonic acid (AA) have been shown to inhibit renal Na+ transport, and inhibition of Cyp-epoxygenase is associated with salt-sensitive hypertension.
Wang MX, Wang LJ, Xiao Y, Zhang DD, Duan XP, Wang WH.   +5 more
europepmc   +2 more sources

Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation [PDF]

, 2011
Background Cytochrome-P450 (CYP450) epoxygenases metabolise arachidonic acid (AA) into four different biologically active epoxyeicosatrienoic acid (EET) regioisomers.
Geisslinger, Gerd, Gerd Geisslinger, Brandes, Ralf P., Brandes, Ralf, Michael J Fischer, Fleming, Ingrid, Scholich, Klaus, Woolf Clifford J, Ralf P Brandes, Clifford J Woolf, Fleming Ingrid, Reeh, Peter Werner, Brenneis Christian, Fischer, Michael, Coste Ovidiu, Coste, Ovidiu, Brandes Ralf P, Kai Altenrath, Reeh Peter W, Christian Brenneis, Scholich Klaus, Sisignano, Marco, Reeh, Peter W., Altenrath Kai, Ingrid Fleming, Peter W Reeh, Woolf, Clifford J., Angioni Carlo, Geisslinger Gerd, Angioni, Carlo Federico, Klaus Scholich, Brenneis, Christian, Ovidiu Coste, Carlo Angioni, Sisignano Marco, Marco Sisignano, Fischer, Michael J., Fischer Michael J, Altenrath, Kai, Angioni, Carlo   +39 more
core   +3 more sources

Lysophosphatidic acids are new substrates for the phosphatase domain of soluble epoxide hydrolase

Journal of Lipid Research, 2012
Soluble epoxide hydrolase (sEH) is a bifunctional enzyme that has a C-terminus epoxide hydrolase domain and an N-terminus phosphatase domain. The endogenous substrates of epoxide hydrolase are known to be epoxyeicosatrienoic acids, but the endogenous ...
Ami Oguro, Susumu Imaoka
doaj   +1 more source